Quantify the Degree of Pain Relief of Pelvic Congestion Syndrome Following Gonadal Vein Embolization

Sponsor
University of Kansas Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT03794466
Collaborator
(none)
30
1
52.5
0.6

Study Details

Study Description

Brief Summary

The primary objective is to quantify the degree of pain relief in patients undergoing gonadal vein embolization with coils as well as identify clinical or imaging factors that are predictive of a positive response to treatment, or poor response to treatment.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Chronic pelvic pain affects almost 40% of women during their lifetime. Pelvic congestion syndrome (PCS) accounts for up to 30% of those with chronic pelvic pain. The most common underlying cause of PCS is incompetence or obstruction of the gonadal veins, resulting in painful congestion of the pelvic and perineal venous vasculature. Medical treatment is first line, and aims to suppress ovarian function and induce vasoconstriction of the venous system. Unfortunately, efficacy and long-term pain relief from medical therapy is limited. Coil embolization of the gonadal veins has been shown to decrease pain in those affected by PCS, although the degree of relief has not yet been quantified.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    30 participants
    Observational Model:
    Other
    Time Perspective:
    Prospective
    Official Title:
    Quantification of Pain Relief With Gonadal Vein Embolization for Pelvic Congestion Syndrome
    Actual Study Start Date :
    May 10, 2019
    Anticipated Primary Completion Date :
    Sep 25, 2022
    Anticipated Study Completion Date :
    Sep 25, 2023

    Outcome Measures

    Primary Outcome Measures

    1. Quantify pain relief using the Pelvic Congestion Symptom Pain Scale after gonadal vein embolization [Change from baseline (before gonadal vein embolization) to 360 days post-procedure.]

      quantify the degree of pain relief in patients undergoing gonadal vein embolization with coils using a survey consisting 4 questions. Answers will be given values 0-4, which higher values are considered to be worse outcomes. One question is "On average, how many days a week do you experience pelvic pain?" Answers would be none (0), 1-2 days a week (1), 3-4 days a week (2), 5-6 days a week (3), and every day of the week (4). Maximum total amount of points will be 16. This is the number of points added together from all 4 questions.

    Secondary Outcome Measures

    1. Predict positive or poor response to gonadal vein embolization treatment [Change from baseline (before gonadal vein embolization) to 360 days post-procedure.]

      Identify clinical or imaging factors that are predictive of a positive response to treatment, or poor response to treatment.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Female patients 18 years of age or older

    • Meet the clinical and imaging criteria for the diagnosis of PCS and have no contraindications to coil embolization of the gonadal veins.

    • Patients who are treated with coil embolization of the gonadal veins in the Interventional Radiology division between October 1, 2018 to October 1, 2019.

    Exclusion Criteria:
    • Patients less than 18 years of age.

    • Patients who are found to have an underlying cause of pelvic congestion syndrome unrelated to venous congestion and insufficiency. This includes, but is not limited to, nutcracker syndrome, or a mass resulting in extrinsic compression of the gonadal veins.

    • Patients who have received prior surgical therapy for PCS, including bilateral salpingo-oophorectomy (TAH-BSO), gonadal vein resection, or gonadal vein ligation.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 The University of Kansas Medical Center Kansas City Kansas United States 66160

    Sponsors and Collaborators

    • University of Kansas Medical Center

    Investigators

    • Principal Investigator: Adam S Alli, MD, The University of Kansas Medical Center

    Study Documents (Full-Text)

    More Information

    Publications

    Responsible Party:
    University of Kansas Medical Center
    ClinicalTrials.gov Identifier:
    NCT03794466
    Other Study ID Numbers:
    • STUDY00143045
    First Posted:
    Jan 7, 2019
    Last Update Posted:
    Sep 29, 2021
    Last Verified:
    Sep 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University of Kansas Medical Center
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 29, 2021